Mustang Bio, Inc. (MBIO)
After hours:
| Previous close | 0.4730 |
| Open | 0.4699 |
| Bid | 0.4803 x 1900 |
| Ask | 0.4837 x 1600 |
| Day's range | 0.4625 - 0.4910 |
| 52-week range | 0.1280 - 6.1800 |
| Volume | |
| Avg. volume | 12,597,966 |
| Market cap | 15.144M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
- Yahoo Finance Video
Citi raises its S&P 500 target, Boeing CEO testifies: Yahoo Finance
The S&P 500 (^GSPC) continues to get bullish calls, with Citi joining Goldman Sachs and Evercore ISI as the latest bank to raise its year-end target for the index. Citi and Goldman Sachs have raised their targets to 5,600 while Evercore ISI has raised it to 6,000. As the tech sector continues to push the market to new heights, the Technology Select Sector SPDR Fund (XLK) is set to give Nvidia (NVDA) a 20% weighting while cutting back on Apple (AAPL). Meanwhile, Boeing (BA) CEO David Calhoun heads to Capitol Hill to testify on the company’s various safety concerns. Wall Street is also digesting May’s retail sales report. Yahoo Finance's top trending tickers include Mustang Bio (MBIO), Qualcomm (QCOM), and Palantir (PLTR). Key guests include:9:00 a.m. ET - Scott Chronert, Citi Head of US Equity Strategy9:30 a.m. ET - Matthew Luzzetti, Deutsche Bank Chief US Economist10:00 a.m. ET - Wei Li, BlackRock Global Chief Investment Strategist10:45 a.m. ET - Amy Wu Silverman, RBC Capital Markets Equity Derivatives Strategist11:15 a.m. ET - Paul Knopp, KPMG US CEO
